Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma.
Thirty-one patients with previously treated small cell bronchogenic carcinoma were treated with split-course radiation therapy and concurrent cisplatin and etoposide. Twenty-four patients (78%) had clinical partial or complete responses. Median survival from the time of salvage was 6.3 months. Fifty-eight percent of the patients failed on therapy initially in sites outside the radiation port. Hematologic toxicity was moderate. Concurrent cisplatin, etoposide, and split-course radiation therapy is feasible and active in the treatment of small cell bronchogenic carcinoma.
Rowland
K M
KM
Division of Medical Oncology, Carle Clinic Association, Urbana, IL 61801.
Bonomi
P
P
Taylor
S G
SG
Maffey
S
S
Reddy
S
S
Lee
M S
MS
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D005047:Etoposide; D002945:Cisplatin